NAGE Nasdaq Medicinal Chemicals & Botanical Products Financials FY2016βFY2025
Niagen Bioscience, Inc. had $129M of revenue in fiscal 2025, up 29.9% on the year before. Over five years, revenue changed +16.9% a year on average.
Last close Β· Oct 23, 2026
$2.43
3.6%Hi! I read Niagen Bioscience, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+29.9%
Yes. Sales grew 29.9% last year.
Does it make a profit?
13.4%
Yes. It keeps 13.4% of every sale as profit.
How healthy are the accounts?
5 / 8
Mixed. It passes 5 of 8 health tests.
How is the share priced?
13.5x
One share costs 13.5 times its yearly profit per share.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Niagen Bioscience, Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 4, 2026
Wednesday Β· in 9 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 4, 2026 | Q2 '26 | After the market closes | 8-K β |
| May 6, 2026 | Q1 '26 | After the market closes | 8-K β |
| Mar 4, 2026 | Q4 '25 | After the market closes | 8-K β |
| Nov 4, 2025 | Q3 '25 | After the market closes | 8-K β |
| Aug 6, 2025 | Q2 '25 | After the market closes | 8-K β |
| May 7, 2025 | Q1 '25 | After the market closes | 8-K β |
| Mar 4, 2025 | Q4 '24 | After the market closes | 8-K β |
| Oct 31, 2024 | Q3 '24 | After the market closes | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Niagen Bioscience, Inc. had $129M of revenue in fiscal 2025, up 29.9% on the year before. Over five years, revenue changed +16.9% a year on average. Its operating margin was 12.6%, up 4.8Β pts: of every 100 in sales, about 13 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Niagen Bioscience, Inc. made $17.4M of net profit in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
KIRA Β· Niagen Bioscience, Inc. returned $0.3M to shareholders in fiscal 2025. The diluted share count rose 9.4%.
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Niagen Bioscience, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $28.2M | $20.3M | $27.2M | $44.5M | $64.8M |
| Interest coverage | β492.2x | β | β | β | β |
| Current ratio | 2.8x | 2.6x | 2.4x | 3.6x | 4.9x |
| Quick ratio | 2.0x | 1.8x | 1.7x | 3.1x | 3.8x |
| Total assets | $57.8M | $54.1M | $55.0M | $68.3M | $106M |
| Total liabilities | $26.1M | $25.4M | $26.5M | $22.2M | $29.9M |
| Shareholders' equity | $31.7M | $28.7M | $28.5M | $46.1M | $76.5M |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Niagen Bioscience, Inc. passes 5 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 4 / 9 | 4 / 9 | 3 / 8 | 4 / 8 | 4 / 8 | 3 / 8 | 5 / 8 | 6 / 8 | 5 / 8 |
| Accruals ratio | 0.0% | β3.8% | β23.6% | β28.4% | β23.7% | β6.2% | β2.6% | β22.1% | β5.8% | 4.4% |
| Altman Z'' | β5.10 | 6.80 | β6.88 | β11.01 | β12.05 | β7.84 | β8.83 | β7.40 | β1.31 | 3.42 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $21.7M | $21.2M | $31.6M | $46.3M | $59.3M | $67.4M | $72.1M | $83.6M | $99.6M | $129M |
| Net interest income | β | β | β | β | β | β$0.1M | $0.0M | $0.7M | β | β |
| Gross profit | $10.4M | $10.5M | $16.1M | $25.8M | $35.3M | $41.5M | $42.8M | $50.8M | $61.6M | $83.2M |
| Research and development | $2.5M | $4.0M | $5.5M | $4.4M | $3.4M | $3.8M | $4.8M | $5.0M | $6.0M | $6.3M |
| Operating income | β$2.9M | β$16.4M | β$33.2M | β$31.3M | β$19.9M | β$27.1M | β$18.6M | β$5.6M | $7.7M | $16.3M |
| Interest expense | $0.3M | $0.2M | $0.1M | $0.8M | $0.1M | $0.1M | β | β | β | β |
| Pretax income | β$3.6M | β$16.5M | β | β | β | β | β | β$4.9M | $8.9M | $18.2M |
| Income tax | $0.0M | $0.0M | β | β | β | β | β | $0.0M | $0.3M | $0.8M |
| Net income | β$2.9M | β$11.4M | β$33.3M | β$32.1M | β$19.9M | β$27.1M | β$16.5M | β$4.9M | $8.6M | $17.4M |
| Diluted EPS | β$0.08 | β$0.26 | β$0.61 | β$0.56 | β$0.33 | β$0.40 | β$0.24 | β$0.07 | $0.11 | $0.20 |
| Diluted shares | 0.04B | 0.00B | 0.00B | 0.06B | 0.06B | 0.07B | 0.07B | 0.07B | 0.08B | 0.09B |
| Cash flow | ||||||||||
| Cash from operations | β$2.9M | β$9.8M | β$20.9M | β$20.4M | β$10.6M | β$24.2M | β$15.1M | $7.1M | $12.1M | $13.5M |
| Capital expenditure | $1.5M | $1.2M | $1.3M | $0.7M | β | β | β | β | β | β |
| Free cash flow | β$4.4M | β$11.0M | β$22.2M | β$21.2M | β | β | β | β | β | β |
| Depreciation and amortization | $0.3M | $0.5M | $0.6M | $0.8M | $0.9M | $0.9M | $0.9M | $0.9M | $0.7M | $0.6M |
| Stock-based compensation | $1.2M | $4.6M | $6.4M | $7.2M | $6.9M | $6.2M | $5.7M | $4.8M | $3.7M | $6.1M |
| Share buybacks | β | $0.0M | $0.4M | β | β | β | β | β | $0.0M | $0.3M |
| Dividends and buybacks | β | $0.0M | $0.4M | β | β | β | β | β | $0.0M | $0.3M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $1.6M | $45.4M | $22.6M | $18.8M | $16.7M | $28.2M | $20.3M | $27.2M | $44.5M | $64.8M |
| Total debt | $0.0M | $0.3M | $0.1M | β | β | β | β | β | β | β |
| Finance lease liabilities | β | β | $0.3M | $0.3M | $0.1M | β | β | β | β | β |
| Current assets | $15.7M | $57.2M | $36.5M | $33.5M | $32.2M | $48.9M | $46.6M | $49.5M | $64.1M | $96.8M |
| Current liabilities | $8.9M | $8.1M | $14.4M | $15.1M | $16.5M | $17.6M | $17.9M | $20.6M | $17.9M | $19.9M |
| Inventory | $7.9M | $5.8M | $8.2M | $11.5M | $11.7M | $13.6M | $14.7M | $14.5M | $9.2M | $20.4M |
| Property and equipment, net | $1.8M | $2.9M | $3.6M | $3.8M | $3.2M | β | β | β | β | β |
| Intangible assets | $0.5M | $1.7M | $1.5M | $1.3M | $1.1M | $0.9M | $0.7M | $0.5M | $0.4M | $5.7M |
| Total assets | $19.8M | $62.7M | $42.2M | $40.2M | $38.4M | $57.8M | $54.1M | $55.0M | $68.3M | $106M |
| Total liabilities | $9.8M | $8.9M | $15.1M | $19.8M | $21.9M | $26.1M | $25.4M | $26.5M | $22.2M | $29.9M |
| Shareholders' equity | $10.0M | $53.8M | $27.2M | $20.4M | $16.4M | $31.7M | $28.7M | $28.5M | $46.1M | $76.5M |
| Margins | ||||||||||
| Gross margin | 48.0% | 49.4% | 50.9% | 55.7% | 59.5% | 61.5% | 59.4% | 60.8% | 61.8% | 64.3% |
| Operating margin | β13.4% | β77.2% | β105.1% | β67.6% | β33.5% | β40.1% | β25.9% | β6.7% | 7.8% | 12.6% |
| EBITDA margin | β11.9% | β74.8% | β103.2% | β66.0% | β32.0% | β38.8% | β24.6% | β5.7% | 8.4% | 13.1% |
| Net margin | β13.5% | β53.7% | β105.6% | β69.4% | β33.6% | β40.2% | β23.0% | β5.9% | 8.6% | 13.4% |
| FCF margin | β20.5% | β51.7% | β70.4% | β45.8% | β | β | β | β | β | β |
| Net interest share of revenue | β | β | β | β | β | β0.1% | 0.0% | 0.8% | β | β |
| Returns | ||||||||||
| Return on capital | β27.5% | β147.8% | β557.7% | β | β | β | β | β | β | β |
| Return on capital employed | β26.7% | β30.0% | β119.4% | β124.3% | β90.7% | β67.3% | β51.5% | β16.3% | 15.4% | 18.8% |
| Return on equity | β29.4% | β35.7% | β82.2% | β135.0% | β108.1% | β112.7% | β54.8% | β17.3% | 22.9% | 28.3% |
| Return on assets | β14.8% | β27.6% | β63.5% | β78.0% | β50.7% | β56.4% | β29.6% | β9.1% | 13.9% | 19.9% |
| Return on tangible equity | β30.9% | β21.8% | β130.0% | β168.0% | β129.9% | β87.9% | β59.1% | β17.7% | 18.7% | 24.5% |
| Growth | ||||||||||
| Revenue growth | β | β2.1% | 48.8% | 46.7% | 28.0% | 13.8% | 6.8% | 16.0% | 19.2% | 29.9% |
| Net income growth | β | β | β | β | β | β | β | β | β | 103.3% |
| EPS growth | β | β | β | β | β | β | β | β | β | 81.8% |
| Share count change | β | β99.9% | 23.3% | 103,638.2% | 7.0% | 10.0% | 3.8% | 7.5% | 4.2% | 9.4% |
| Financial health | ||||||||||
| Debt / equity | 0.0x | 0.0x | 0.0x | β | β | β | β | β | β | β |
| Interest coverage | β8.7x | β107.0x | β419.9x | β37.0x | β279.6x | β492.2x | β | β | β | β |
| Current ratio | 1.8x | 7.1x | 2.5x | 2.2x | 2.0x | 2.8x | 2.6x | 2.4x | 3.6x | 4.9x |
| Quick ratio | 0.9x | 6.4x | 2.0x | 1.5x | 1.2x | 2.0x | 1.8x | 1.7x | 3.1x | 3.8x |
| Capital allocation | ||||||||||
| Capex / revenue | 6.9% | 5.5% | 4.2% | 1.6% | β | β | β | β | β | β |
| Stock comp / revenue | 5.5% | 21.7% | 20.2% | 15.5% | 11.7% | 9.2% | 8.0% | 5.7% | 3.7% | 4.7% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 4.0 | 4.0 | 3.0 | 4.0 | 4.0 | 3.0 | 5.0 | 6.0 | 5.0 |
| Altman Z'' | β5.1 | 6.8 | β6.9 | β11.0 | β12.1 | β7.8 | β8.8 | β7.4 | β1.3 | 3.4 |
| Accruals ratio | 0.0% | β3.8% | β23.6% | β28.4% | β23.7% | β6.2% | β2.6% | β22.1% | β5.8% | 4.4% |
Source: SEC EDGAR XBRL filings (CIK 0001386570). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
